Pharmacogenetics of colorectal cancer

Colorectal cancer is one of the most common types of cancer in both men and women. Multiple chemotherapy combinations exist; however, there is currently no strategy for individualised therapy selection prior to treatment. Genetic polymorphisms in genes involved in the metabolism, transport or targets for the commonly used chemotherapy drugs (5-fluorouracil, irinotecan and oxaliplatin) have been described. Many require validation in large prospective trials before they can be used as markers for outcome and/or toxicity. This review describes the data available on polymorphisms in key genes that are associated with chemotherapy toxicity and response in colorectal cancer.

[1]  Daniel J Sargent,et al.  A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  B. Giraudeau,et al.  ERCC1 Codon 118 Polymorphism Is a Predictive Factor for the Tumor Response to Oxaliplatin/5-Fluorouracil Combination Chemotherapy in Patients with Advanced Colorectal Cancer , 2005, Clinical Cancer Research.

[3]  R. Diasio,et al.  Analysis of the DPYD Gene Implicated in 5-Fluorouracil Catabolism in a Cohort of Caucasian Individuals , 2005, Clinical Cancer Research.

[4]  H. McLeod,et al.  Pharmacogenetics goes 3D , 2005, Nature Genetics.

[5]  J. Fleshman,et al.  Genotype-guided neoadjuvant therapy for rectal cancer , 2005 .

[6]  A. Syvänen.  Toward genome-wide SNP genotyping , 2005, Nature Genetics.

[7]  D. Sargent,et al.  Glutathione S-transferase P1 I105V (GSTP1 I105V) polymorphism is associated with early onset of oxaliplatin-induced neurotoxicity , 2005 .

[8]  G. Rosner,et al.  Irinotecan (CPT-11) pharmacokinetics (PK) and neutropenia: interaction among UGT1A1 and transporter genes , 2005 .

[9]  S. Groshen,et al.  Molecular determinants of cetuximab efficacy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  J. Berlin,et al.  Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Silvia Benvenuti,et al.  Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. , 2005, The Lancet. Oncology.

[12]  Y. Cheung,et al.  Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer. , 2005, British journal of clinical pharmacology.

[13]  M. Baiget,et al.  Single nucleotide polymorphism in the 5′ tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracil‐based chemotherapy in advanced colorectal cancer patients , 2004, International journal of cancer.

[14]  J. Robert,et al.  Pharmacogenetics of human carboxylesterase 2, an enzyme involved in the activation of irinotecan into SN‐38 , 2004, Clinical pharmacology and therapeutics.

[15]  N. Magné,et al.  Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients. , 2004, Pharmacogenetics.

[16]  H. McLeod.  Drug pathways: moving beyond single gene pharmacogenetics. , 2004, Pharmacogenomics.

[17]  P. Kwok,et al.  Pharmacogenomic assessment of carboxylesterases 1 and 2. , 2004, Genomics.

[18]  E. Cook,et al.  Determination and analysis of single nucleotide polymorphisms and haplotype structure of the human carboxylesterase 2 gene. , 2004, Pharmacogenetics.

[19]  M. Taron,et al.  Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  A. Russo,et al.  UGT1A1*28 polymorphism in ovarian cancer patients. , 2004, Oncology reports.

[21]  M. Baiget,et al.  UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer , 2004, British Journal of Cancer.

[22]  Armando Santoro,et al.  Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. , 2004, The New England journal of medicine.

[23]  Deborah Schrag,et al.  The price tag on progress--chemotherapy for colorectal cancer. , 2004, The New England journal of medicine.

[24]  G. Samimi,et al.  Increased Expression of the Copper Efflux Transporter ATP7A Mediates Resistance to Cisplatin, Carboplatin, and Oxaliplatin in Ovarian Cancer Cells , 2004, Clinical Cancer Research.

[25]  Sharon Marsh,et al.  Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype , 2004, Clinical pharmacology and therapeutics.

[26]  D. Neuberg,et al.  XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  S. Groshen,et al.  A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer , 2004, British Journal of Cancer.

[28]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[29]  Youngchul Kim,et al.  Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. , 2004, Lung cancer.

[30]  H. McLeod,et al.  Application of pharmacogenomics in the individualization of chemotherapy for gastrointestinal malignancies. , 2004, Clinical colorectal cancer.

[31]  Y. Pommier,et al.  ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan‐treated metastases , 2004, International journal of cancer.

[32]  R. Pazdur,et al.  Progress in the development of novel treatments for colorectal cancer. , 2004, Oncology.

[33]  S. Groshen,et al.  A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. , 2004, Pharmacogenetics.

[34]  Soma Das,et al.  Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  K. Ogawa,et al.  Prognostic Value of the Cu-Transporting ATPase in Ovarian Carcinoma Patients Receiving Cisplatin-Based Chemotherapy , 2004, Clinical Cancer Research.

[36]  P. Kwok,et al.  High-throughput Genotyping Methods for Pharmacogenomic Studies , 2004 .

[37]  Jeffrey W. Clark,et al.  Dihydropyrimidine dehydrogenase and thymidylate synthase polymorphisms and their association with 5-fluorouracil/leucovorin chemotherapy in colorectal cancer. , 2004, Clinical colorectal cancer.

[38]  M. Lucock,et al.  Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate. , 2004, Journal of the National Cancer Institute.

[39]  P. Laurent-Puig,et al.  Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms: relationships with 5-fluorouracil sensitivity , 2004, British Journal of Cancer.

[40]  P. Kwok,et al.  Methods for genotyping single nucleotide polymorphisms. , 2003, Annual review of genomics and human genetics.

[41]  G. Watanabe,et al.  Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene. , 2003, Cancer research.

[42]  Sharon Marsh,et al.  Irinotecan pathway genotype analysis to predict pharmacokinetics. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[43]  Martin R. Johnson,et al.  Denaturing high performance liquid chromatography analysis of the DPYD gene in patients with lethal 5-fluorouracil toxicity. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[44]  H. Lenz,et al.  A novel single nucleotide polymorphism within the 5' tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. , 2003, Cancer research.

[45]  A. Sparreboom,et al.  Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. , 2003, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[46]  Howard L McLeod,et al.  Pharmacogenomics--drug disposition, drug targets, and side effects. , 2003, The New England journal of medicine.

[47]  J. Watters,et al.  Recent advances in the pharmacogenetics of cancer chemotherapy. , 2002, Current opinion in molecular therapeutics (Print).

[48]  A. V. van Kuilenburg,et al.  High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity. , 2002, Pharmacogenetics.

[49]  Y. Sugiyama,et al.  Reduced Gastrointestinal Toxicity Following Inhibition of the Biliary Excretion of Irinotecan and Its Metabolites by Probenecid in Rats , 2002, Pharmaceutical Research.

[50]  Sharon Marsh,et al.  SNP databases and pharmacogenetics: great start, but a long way to go , 2002, Human mutation.

[51]  S. Groshen,et al.  Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. , 2002, Journal of the National Cancer Institute.

[52]  Y. Miki,et al.  C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. , 2002, Molecular cancer therapeutics.

[53]  S. Groshen,et al.  A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. , 2001, Cancer research.

[54]  G. Watanabe,et al.  Different lengths of a polymorphic repeat sequence in the thymidylate synthase gene affect translational efficiency but not its gene expression. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[55]  U. Brinkmann,et al.  Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[56]  E. Bowman,et al.  Functional significance of XPD polymorphic variants: attenuated apoptosis in human lymphoblastoid cells with the XPD 312 Asp/Asp genotype. , 2001, Cancer research.

[57]  H. McLeod,et al.  Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer. , 2001, International journal of oncology.

[58]  D. Sargent,et al.  Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. , 2001, The New England journal of medicine.

[59]  J. García-Foncillas,et al.  Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  J P Pignon,et al.  Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. , 2001, The New England journal of medicine.

[61]  A Rzhetsky,et al.  The human ATP-binding cassette (ABC) transporter superfamily. , 2001, Journal of lipid research.

[62]  C. Ulrich,et al.  Searching expressed sequence tag databases: discovery and confirmation of a common polymorphism in the thymidylate synthase gene. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[63]  J. Schellens,et al.  Transport of Topoisomerase I Inhibitors by the Breast Cancer Resistance Protein: Potential Clinical Implications , 2000, Annals of the New York Academy of Sciences.

[64]  H. McLeod,et al.  Novel thymidylate synthase enhancer region alleles in African populations , 2000, Human mutation.

[65]  A Gouyette,et al.  Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[66]  M. Relling,et al.  Pharmacogenomics: translating functional genomics into rational therapeutics. , 1999, Science.

[67]  H. McLeod,et al.  Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations. , 1999, Genomics.

[68]  A. Di Rienzo,et al.  Phenotype‐genotype correlation of in vitro SN‐38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism , 1999, Clinical pharmacology and therapeutics.

[69]  H. McLeod,et al.  Characterization of the human dihydropyrimidine dehydrogenase gene. , 1998, Genomics.

[70]  E. Beutler,et al.  Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[71]  S. Groshen,et al.  Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  D Lindhout,et al.  The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. , 1995, The New England journal of medicine.

[73]  N. Horie,et al.  Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5'-terminal regulatory region of the human gene for thymidylate synthase. , 1995, Cell structure and function.

[74]  P. Johnston,et al.  Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. , 1995, Cancer research.

[75]  H E Rockette,et al.  The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[76]  J. Laurie,et al.  Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  C. Heidelberger,et al.  Fluorinated Pyrimidines, A New Class of Tumour-Inhibitory Compounds , 1957, Nature.

[78]  S. Howell,et al.  Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. , 2005, Critical reviews in oncology/hematology.

[79]  M. Mathieu,et al.  Malignant breast tumors after radiotherapy for a first cancer during childhood. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[80]  H. McLeod,et al.  ABCG2 Pharmacogenetics: Ethnic Differences in Allele Frequency and Assessment of Influence on Irinotecan Disposition , 2004 .

[81]  M. Relling,et al.  Pharmacogenetic analysis of interindividual irinotecan (CPT-11) pharmacokinetic (PK) variability: Evidence for a functional variant of ABCC2. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[82]  Teruhiko Yoshida,et al.  Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan. , 2003, Pharmacogenetics.

[83]  Y. Sugiyama,et al.  The potential for an interaction between MRP2 (ABCC2) and various therapeutic agents: probenecid as a candidate inhibitor of the biliary excretion of irinotecan metabolites. , 2002, Drug metabolism and pharmacokinetics.

[84]  J. Edwards,et al.  Extra Adverse drug reactions in hospital patients A systematic review of the prospective and retrospective studies , 2002 .

[85]  M. Manns,et al.  UDP-glucuronosyltransferase activity in human liver and colon. , 1999, Gastroenterology.